Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1254 • ACR Convergence 2021
The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients
Anna Abou-Raya, Darwish ELHallous, Mohamed Ossama, Nahla Farahat, Mohamed Khaled and Suzan Abou-Raya, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic immune-mediated heterogenous disease characterized by a defect in the compartment of regulatory CD4+Foxp3+ T cells (Treg) which are…
Abstract Number: 1675 • ACR Convergence 2021
Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Rishi Desai, Hemin Lee, Su Been Lee and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Initial reports from “ORAL Surveillance” post-marketing safety trial have suggested that tofacitinib, in comparison with tumor necrosis factor inhibitors (TNFI), may be associated with…
Abstract Number: 1914 • ACR Convergence 2021
Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
Jonah Levine¹, Deanna Jannat-Khah¹, Vivian Bykerk², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases (SRD) may have modified their medications at the time of…
Abstract Number: 0146 • ACR Convergence 2021
Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
Akrithi Udupa¹, Catherine Sims², Poorva Apte², Megan Milne², Isaac Smith¹, D Ryan Anderson¹, Mithu Maheswaranathan², Jayanth Doss² and David Leverenz², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: The COVID-19 pandemic led to the rapid implementation of telehealth in rheumatology with unknown implications for medication toxicity lab monitoring. The purpose of this…
Abstract Number: 0671 • ACR Convergence 2021
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
Aaron Broadwell¹, John Albert², Brian LaMoreaux³ and Lissa Padnick-Silver³, ¹Rheumatology and Osteoporosis Specialists, Shreveport, LA, ²Rheumatic Disease Center, Milwaukee, WI, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…
Abstract Number: 0958 • ACR Convergence 2021
Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Maya Buch², Maxime Dougados³, Deepak L Bhatt⁴, Jon Giles⁵, Ivana Vranic⁶, Joseph Wu⁷, Cunshan Wang⁷, Sujatha Menon⁷, Jose L Rivas⁸, Arne Yndestad⁹, Carol A Connell⁷ and Zoltan Szekanecz¹⁰, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²University of Leeds, Leeds, United Kingdom, ³Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁴Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵Columbia University, New York, NY, ⁶Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer SLU, Madrid, Spain, ⁹Pfizer Inc, Oslo, Norway, ¹⁰Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: To identify independent risk factors for major adverse cardiovascular (CV) events (MACE) in ORAL Surveillance (NCT02092467), a long-term, randomized, open-label, non-inferiority, Phase 3b/4 safety…
Abstract Number: 1316 • ACR Convergence 2021
Vitamin D Deficiency and Disease Activity in Patients with Spondyloarthritis
Maria Rato¹, Filipe Pinheiro¹, Salomé Garcia¹, Bruno Fernandes², Ana Martins¹, Daniela Oliveira¹, Frederico Martins³, Diogo Fonseca⁴, Alexandra Bernardo¹, Miguel Bernardes¹ and Lúcia Costa¹, ¹Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ²Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário do Algarve EPE, Algarve, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Gaia, Portugal
Background/Purpose: There are increasing data about vitamin D immunomodulatory potential in different rheumatologic disorders. Deficiency of vitamin D is frequent in patients with spondyloarthritis (SpA)…
Abstract Number: 1677 • ACR Convergence 2021
Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
Yusuke Miwa¹ and Yuko Mitamura², ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: Rheumatoid arthritis (RA) and dyslipidemia are associated with inflammation. Although the low-density lipoprotein cholesterol (LDL-C) is normal range, the high-density lipoprotein cholesterol (HDL-C) is…
Abstract Number: 1939 • ACR Convergence 2021
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
Abstract Number: 0147 • ACR Convergence 2021
A Qualitative Analysis of Methotrexate Self-Injection Education Videos on YouTube: An Update
Amy Semaka, Hillary Wilson and Steven Katz, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Patients are turning to the Internet for guidance and information at an increasing rate, requiring clinicians to be aware of the constantly changing resources…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, Mary Ellen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Marc Natter¹¹ and The STOP-JIA CARRA Registry Investigators¹², ¹Hackensack University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Boston Children's Hospital, Boston, MA, ¹²Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1348 • ACR Convergence 2021
Predictors for Achievement of Low Disease Activity at Week 56 in Patients with Psoriatic Arthritis Who Received Upadacitinib 15 Mg Once Daily: Pooled Analysis of Two Phase 3 Studies
Daniel Aletaha¹, Philip Mease², Ralph Lippe³, Frank Behrens⁴, Derek Haaland⁵, Penélope Palominos⁶, Apinya Lertratanakul⁷, Michael Lane⁸, Kevin Douglas⁷, Peter Nash⁹ and Arthur Kavanaugh¹⁰, ¹Medical University Vienna, Vienna, Austria, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁴Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁵McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, ⁶Division of Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc., North Chicago, ⁹Griffith University, Brisbane, Australia, ¹⁰Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Upadacitinib (UPA) 15 mg once daily (QD) has demonstrated efficacy and safety in patients with psoriatic arthritis (PsA) for up to 56 weeks in…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 1940 • ACR Convergence 2021
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Jeffrey Curtis¹, Kunihiro Yamaoka², Yi-Hsing Chen³, Levent M Gunay⁴, Naonobu Sugiyama⁵, Carol A Connell⁶, Cunshan Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Ivana Vranic⁷ and Juan J Gomez-Reino⁸, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Inc, Istanbul, Turkey, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁸Hospital Clínico Universitario, Santiago de Compostela, Spain
Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].